Browse

Case Information


Intellikine: Build-to-Sell in Biotech
Lasky, Larry
Publication date: 2/1/2013, pages 1-11

The Intellikine case study provides an example of a biotech company where its management team, founders, and investors sold the company at a relatively early stage of the company’s development. In early 2012, Troy Wilson, the CEO of Intellikine sold the company to Millennium: The Takeda Oncology Company, Takeda’s business unit responsible for global oncology, strategy, and development. The deal was for as much as $310 million (Millennium would pay $190 million upfront, with an additional $120 million dependent on clinical development milestones). By 2011, the Intellikine team had advanced three programs into human clinical testing. The key question for students is whether Wilson and his team sold the company too early or not. Various perspectives and the company strategy and execution are provided in the case study to allow students to have a fruitful discussion on each side of the argument.
 


Educators may request a complimentary preview before purchasing. To find out more, please read about our publishing partnerships.

To request permission, please submit a Copyright Permission Request Form.